Clinical Report: Overexpression of GLP-1R in Thyroid Carcinoma

Overview

This study identifies a unique immunogenetic group in thyroid carcinoma characterized by high glucagon-like peptide-1 receptor (GLP-1R) expression, particularly in metastatic papillary thyroid carcinoma (PTC). The findings suggest a need for further investigation into the implications of GLP-1R overexpression in the context of GLP-1 receptor agonist therapies.

Background

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has increased significantly for diabetes and weight management, raising concerns about their potential link to medullary thyroid carcinoma (MTC). Understanding GLP-1R expression in thyroid cancers is crucial, as it may influence treatment decisions and patient outcomes.

Data Highlights

Key Findings

• Metastatic PTC exhibited the highest GLP-1R mRNA expression among various cancers.
• Flow cytometric analysis confirmed increased GLP-1R protein expression in metastatic thyroid carcinomas.
• High GLP-1R expression correlated with distinct immunogenetic transcriptional profiles.
• Downregulation of immune pathways was observed in tumors with elevated GLP-1R levels.
• Decreased immune cell infiltration was associated with high GLP-1R expression in thyroid cancers.

Clinical Implications

The identification of high GLP-1R expression in metastatic thyroid carcinomas may necessitate careful consideration of GLP-1 RA therapies in affected patients. Clinicians should remain vigilant regarding the potential oncogenic implications of GLP-1R overexpression in thyroid cancer management.

Conclusion

The study highlights the significance of GLP-1R expression in thyroid carcinomas, particularly in metastatic cases, warranting further research into its clinical implications.

Related Resources & Content

1. The Journal of Clinical Endocrinology & Metabolism, 2023 -- Evaluating Patients with Thyroid Nodules: The Role of GLP-1 Receptor Agonists
2. JAMA Network Open, 2023 -- GLP-1 Receptor Agonists and Cancer—The Promise Is Real
3. The Journal of Clinical Endocrinology & Metabolism, 2023 -- GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization
4. The ASCO Post, 2026 -- GLP-1 RAs May Reduce Metastatic Progression in Certain Obesity-Related Cancers
5. WEGOVY (Novo Nordisk): FDA Package Insert
6. FDA Package Insert for WEGOVY
7. Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
8. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study
9. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
10. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials - PubMed
11. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis - PubMed
12. Additional Considerations Regarding GLP-1RA Use and Thyroid Cancer Risk | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
13. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 2023 | European Medicines Agency (EMA)